Cynata Therapeutics Ltd Net Assets
Cynata Therapeutics Ltd net assets. Based on the latest financial reports, Cynata Therapeutics Ltd (CYP) has net assets worth AU$5.98 Million AUD (≈ $4.23 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$7.20 Million ≈ $5.09 Million USD) and total liabilities (AU$1.22 Million ≈ $860.53K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CYP shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$5.98 Million |
| % of Total Assets | 83.1% |
| Annual Growth Rate | 3.17% |
| 5-Year Change | -78.92% |
| 10-Year Change | -30.31% |
| Growth Volatility | 121.32 |
Net Assets of Cynata Therapeutics Ltd (2007–2025)
Net assets of Cynata Therapeutics Ltd from 2007 to 2025. This chart illustrates how Cynata Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. See CYP equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Cynata Therapeutics Ltd (2007–2025)
The table below shows the annual net assets of Cynata Therapeutics Ltd from 2007 to 2025. For live market cap and overall valuation, see Cynata Therapeutics Ltd (CYP) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$5.98 Million ≈ $4.23 Million |
-17.12% |
| 2024-06-30 | AU$7.22 Million ≈ $5.11 Million |
-56.87% |
| 2023-06-30 | AU$16.73 Million ≈ $11.84 Million |
-30.16% |
| 2022-06-30 | AU$23.96 Million ≈ $16.95 Million |
-15.55% |
| 2021-06-30 | AU$28.37 Million ≈ $20.08 Million |
+68.98% |
| 2020-06-30 | AU$16.79 Million ≈ $11.88 Million |
+53.04% |
| 2019-06-30 | AU$10.97 Million ≈ $7.76 Million |
-28.70% |
| 2018-06-30 | AU$15.39 Million ≈ $10.89 Million |
+10.98% |
| 2017-06-30 | AU$13.86 Million ≈ $9.81 Million |
+61.53% |
| 2016-06-30 | AU$8.58 Million ≈ $6.07 Million |
-1.91% |
| 2015-06-30 | AU$8.75 Million ≈ $6.19 Million |
-11.21% |
| 2014-06-30 | AU$9.85 Million ≈ $6.97 Million |
+499.85% |
| 2013-06-30 | AU$1.64 Million ≈ $1.16 Million |
+92.43% |
| 2012-06-30 | AU$853.75K ≈ $604.08K |
-12.16% |
| 2011-06-30 | AU$971.93K ≈ $687.70K |
+4.28% |
| 2010-06-30 | AU$932.00K ≈ $659.45K |
-3.12% |
| 2009-06-30 | AU$961.98K ≈ $680.66K |
-56.48% |
| 2008-06-30 | AU$2.21 Million ≈ $1.56 Million |
-35.17% |
| 2007-06-30 | AU$3.41 Million ≈ $2.41 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cynata Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8989377100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Cynata Therapeutics Ltd Net Assets Breakdown (June 2025)
Cynata Therapeutics Ltd net assets breakdown by equity component as of June 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$89.52 Million | 1496.54% |
| Other Comprehensive Income | AU$8.17 Million | 136.61% |
| Total Equity | AU$5.98 Million | 100.00% |
Cynata Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Cynata Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Crest Nicholson Holdings plc
LSE:CRST
|
$2.02 Million |
|
Next Mediaworks Limited
NSE:NEXTMEDIA
|
$2.03 Million |
|
Proven Vct PLC
LSE:PVN
|
$2.03 Million |
|
AFC Energy plc
LSE:AFC
|
$2.03 Million |
|
AIS Resources Ltd
V:AIS
|
$2.02 Million |
|
Quinsam Capital Corporation
F:0Q4
|
$2.01 Million |
|
CFI-Compagnie Foncière Internationale
PA:CFI
|
$2.01 Million |
|
ETHERNITY NETW.(DI) -001
F:82N
|
$2.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cynata Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,217,235 to 5,981,735, a change of -1,235,500 (-17.1%).
- Net loss of 9,390,586 reduced equity.
- Share repurchases of 522,264 reduced equity.
- New share issuances of 8,136,935 increased equity.
- Other comprehensive income increased equity by 260,475.
- Other factors increased equity by 279,940.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-9.39 Million | -156.99% |
| Share Repurchases | AU$522.26K | -8.73% |
| Share Issuances | AU$8.14 Million | +136.03% |
| Other Comprehensive Income | AU$260.48K | +4.35% |
| Other Changes | AU$279.94K | +4.68% |
| Total Change | AU$- | -17.12% |
Book Value vs Market Value Analysis
This analysis compares Cynata Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.41x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.01x to 0.41x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-06-30 | AU$0.99 | AU$0.01 | x |
| 2008-06-30 | AU$0.65 | AU$0.01 | x |
| 2009-06-30 | AU$0.28 | AU$0.01 | x |
| 2010-06-30 | AU$0.24 | AU$0.01 | x |
| 2011-06-30 | AU$0.19 | AU$0.01 | x |
| 2012-06-30 | AU$0.09 | AU$0.01 | x |
| 2013-06-30 | AU$0.07 | AU$0.01 | x |
| 2014-06-30 | AU$0.22 | AU$0.01 | x |
| 2015-06-30 | AU$0.14 | AU$0.01 | x |
| 2016-06-30 | AU$0.12 | AU$0.01 | x |
| 2017-06-30 | AU$0.17 | AU$0.01 | x |
| 2018-06-30 | AU$0.17 | AU$0.01 | x |
| 2019-06-30 | AU$0.11 | AU$0.01 | x |
| 2020-06-30 | AU$0.16 | AU$0.01 | x |
| 2021-06-30 | AU$0.22 | AU$0.01 | x |
| 2022-06-30 | AU$0.17 | AU$0.01 | x |
| 2023-06-30 | AU$0.12 | AU$0.01 | x |
| 2024-06-30 | AU$0.04 | AU$0.01 | x |
| 2025-06-30 | AU$0.03 | AU$0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cynata Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -156.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -498.14%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.20x
- Recent ROE (-156.99%) is below the historical average (-92.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -67.25% | -424.10% | 0.15x | 1.05x | AU$-1.71 Million |
| 2009 | -150.76% | 0.00% | 0.00x | 1.48x | AU$-1.55 Million |
| 2010 | -227.05% | -1858.22% | 0.09x | 1.34x | AU$-2.21 Million |
| 2011 | -263.91% | -1150.54% | 0.18x | 1.25x | AU$-2.66 Million |
| 2012 | -180.65% | -949.39% | 0.16x | 1.19x | AU$-1.63 Million |
| 2013 | -55.74% | -2696.09% | 0.02x | 1.09x | AU$-1.08 Million |
| 2014 | -30.85% | -12130.51% | 0.00x | 1.01x | AU$-4.03 Million |
| 2015 | -42.42% | -1299.82% | 0.03x | 1.04x | AU$-4.59 Million |
| 2016 | -57.55% | -449.16% | 0.12x | 1.05x | AU$-5.80 Million |
| 2017 | -32.84% | -260.37% | 0.12x | 1.03x | AU$-5.94 Million |
| 2018 | -29.68% | -332.05% | 0.09x | 1.05x | AU$-6.10 Million |
| 2019 | -77.22% | -647.44% | 0.11x | 1.12x | AU$-9.57 Million |
| 2020 | -21.67% | -51.90% | 0.40x | 1.04x | AU$-5.32 Million |
| 2021 | -27.10% | -497.38% | 0.05x | 1.06x | AU$-10.53 Million |
| 2022 | -22.73% | -70.08% | 0.29x | 1.11x | AU$-7.84 Million |
| 2023 | -85.32% | -863.05% | 0.09x | 1.14x | AU$-15.95 Million |
| 2024 | -135.02% | -420.82% | 0.28x | 1.16x | AU$-10.47 Million |
| 2025 | -156.99% | -498.14% | 0.26x | 1.20x | AU$-9.99 Million |
Industry Comparison
This section compares Cynata Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,206,087
- Average return on equity (ROE) among peers: -128.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cynata Therapeutics Ltd (CYP) | AU$5.98 Million | -67.25% | 0.20x | $2.02 Million |
| Adalta Ltd (1AD) | $7.49 Million | -79.00% | 0.24x | $5.41 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $4.14 Million | -76.87% | 0.39x | $12.88 Million |
| ACRUX Ltd (ACR) | $11.28 Million | 0.00% | 0.07x | $2.61 Million |
| Actinogen Medical Ltd (ACW) | $346.99K | -440.69% | 0.34x | $92.21 Million |
| Argenica Therapeutics Ltd (AGN) | $7.67 Million | -62.81% | 0.24x | $8.63 Million |
| Arovella Therapeutics Ltd (ALA) | $3.77 Million | -28.27% | 0.24x | $42.76 Million |
| Anatara Lifesciences Ltd (ANR) | $535.97K | -364.70% | 1.14x | $1.40 Million |
| Alterity Therapeutics Ltd (ATH) | $16.68 Million | -32.69% | 0.05x | $108.75 Million |
| Amplia Therapeutics Ltd (ATX) | $8.61 Million | -25.79% | 0.06x | $32.32 Million |
| Avecho Biotechnology Ltd (AVE) | $51.55 Million | -176.92% | 0.34x | $32.81 Million |
About Cynata Therapeutics Ltd
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host … Read more